RT Journal Article
T1 Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.
A1 Luque Carmona, Ana María
A1 Ontanilla-Clavijo, Guillermo
A1 Leo Carnerero, Eduardo
AB Immunotherapy is gaining significance in the management of oncological disease. It has demonstrated high levels of efficacy, though it also has hitherto unknown side effects, such as colitis. We present the first case of immune checkpoint inhibitor colitis (nivolumab+ipilimumab) refractory to corticoids treated in our hospital.
SN 1130-0108
YR 2020
FD 2020
LK http://hdl.handle.net/10668/16420
UL http://hdl.handle.net/10668/16420
LA en
DS RISalud
RD Apr 19, 2025